Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

This phase 1 trial is testing an experimental therapy called SYS6020 for people with refractory generalized myasthenia gravis, a chronic autoimmune condition that causes severe muscle weakness. SYS6020 uses a patient's own immune cells, engineered to target BCMA, a protein involv…

This study tests whether adding a targeted drug (sirolimus) to a standard hormone-blocking injection (octreotide) can better control advanced neuroendocrine tumors of the stomach, intestines, or pancreas. About 298 adults with tumors that cannot be removed by surgery will receive…

This study tests an experimental drug called CM326, given as a shot, in 318 people with moderate-to-severe COPD. The goal is to see if it can reduce the number of serious flare-ups over 24 to 52 weeks compared to a placebo. Participants must be at least 40 years old, have had COP…

This study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants…

This study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first t…

This trial checks whether a new strength of ammoxetine hydrochloride enteric-coated tablets works the same as the original version in healthy adults. It also looks at how a high-fat meal affects the drug's absorption. Participants take single doses of both formulations, and resea…

This Phase 1 trial studies how the drug ammoxetine hydrochloride is processed in people with moderate kidney impairment compared to those with normal kidney function. Sixteen adults receive the drug daily for six days, and researchers measure drug levels in blood and urine. The g…

This trial investigates how ammoxetine, a drug given as an enteric-coated tablet, is processed by the body in people with mild or moderate liver impairment compared to those with normal liver function. Participants take a 20 mg dose daily for six days, and researchers measure dru…

This Phase 1 trial is testing a new drug called SYH2085 in 74 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive either a single dose of SYH2085 or a placebo, and the study also looks at how food affects the drug. This is an early step…